
Neil O Carragher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/259081/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The role of focal-adhesion kinase in cancer — a new therapeutic opportunity. Nature Reviews Cancer, 2005, 5, 505-515.	12.8	932
2	Screening out irrelevant cell-based models of disease. Nature Reviews Drug Discovery, 2016, 15, 751-769.	21.5	402
3	The calpain system and cancer. Nature Reviews Cancer, 2011, 11, 364-374.	12.8	333
4	Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends in Cell Biology, 2004, 14, 241-249.	3.6	330
5	v-SRC'S hold over actin and cell adhesions. Nature Reviews Molecular Cell Biology, 2002, 3, 233-245.	16.1	286
6	Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a bioorthogonally activated prodrug approach. Nature Communications, 2014, 5, 3277.	5.8	264
7	Degraded Collagen Fragments Promote Rapid Disassembly of Smooth Muscle Focal Adhesions That Correlates with Cleavage of Pp125FAK, Paxillin, and Talin. Journal of Cell Biology, 1999, 147, 619-630.	2.3	229
8	Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology, 2009, 3, 248-261.	2.1	190
9	Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. Cancer Cell, 2015, 27, 85-96.	7.7	188
10	FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis. Journal of Experimental Medicine, 2015, 212, 1433-1448.	4.2	186
11	A Novel Role for FAK as a Protease-Targeting Adaptor Protein. Current Biology, 2003, 13, 1442-1450.	1.8	177
12	Development and Bioorthogonal Activation of Palladium-Labile Prodrugs of Gemcitabine. Journal of Medicinal Chemistry, 2014, 57, 5395-5404.	2.9	169
13	Comparison of Methods for Image-Based Profiling of Cellular Morphological Responses to Small-Molecule Treatment. Journal of Biomolecular Screening, 2013, 18, 1321-1329.	2.6	166
14	Bistability in the Rac1, PAK, and RhoA Signaling Network Drives Actin Cytoskeleton Dynamics and Cell Motility Switches. Cell Systems, 2016, 2, 38-48.	2.9	159
15	Role of Discoidin Domain Receptors 1 and 2 in Human Smooth Muscle Cell-Mediated Collagen Remodeling. American Journal of Pathology, 2004, 164, 1575-1585.	1.9	158
16	Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report. Molecular and Cellular Proteomics, 2014, 13, 1625-1643.	2.5	152
17	High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells. Molecular Cancer Therapeutics, 2010, 9, 1913-1926.	1.9	147
18	Developments in preclinical cancer imaging: innovating the discovery of therapeutics. Nature Reviews Cancer, 2014, 14, 314-328.	12.8	134

#	Article	IF	CITATIONS
19	Calpain: a role in cell transformation and migration. International Journal of Biochemistry and Cell Biology, 2002, 34, 1539-1543.	1.2	130
20	Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53. Cancer Research, 2011, 71, 747-757.	0.4	127
21	Cleavage of Focal Adhesion Kinase by Different Proteases during Src-regulated Transformation and Apoptosis. Journal of Biological Chemistry, 2001, 276, 4270-4275.	1.6	125
22	Monocytes Differentiate to Immune Suppressive Precursors of Metastasis-Associated Macrophages in Mouse Models of Metastatic Breast Cancer. Frontiers in Immunology, 2017, 8, 2004.	2.2	122
23	Inhibition of calpain stabilises podosomes and impairs dendritic cell motility. Journal of Cell Science, 2006, 119, 2375-2385.	1.2	115
24	Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer. Cancer Research, 2013, 73, 4674-4686.	0.4	111
25	The Extracellular Matrix Dynamically Regulates Smooth Muscle Cell Responsiveness to PDGF ^a . Annals of the New York Academy of Sciences, 2000, 902, 39-52.	1.8	81
26	Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. EMBO Molecular Medicine, 2013, 5, 1335-1350.	3.3	80
27	Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site. Journal of Clinical Medicine, 2020, 9, 1473.	1.0	73
28	Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells. Proceedings of the United States of America, 2015, 112, E3800-5.	3.3	71
29	ADF and Cofilin1 Control Actin Stress Fibers, Nuclear Integrity, and Cell Survival. Cell Reports, 2015, 13, 1949-1964.	2.9	70
30	Inhibition of NF-κB Signaling Ablates the Invasive Phenotype of Glioblastoma. Molecular Cancer Research, 2013, 11, 1611-1623.	1.5	66
31	Real-time Study of E-Cadherin and Membrane Dynamics in Living Animals: Implications for Disease Modeling and Drug Development. Cancer Research, 2009, 69, 2714-2719.	0.4	64
32	Concerns, challenges and promises of high-content analysis of 3D cellular models. Nature Reviews Drug Discovery, 2018, 17, 606-606.	21.5	64
33	Palladium-Mediated Dealkylation of N-Propargyl-Floxuridine as a Bioorthogonal Oxygen-Independent Prodrug Strategy. Scientific Reports, 2015, 5, 9329.	1.6	61
34	Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug Discovery. Pharmaceutics, 2011, 3, 141-170.	2.0	60
35	TRPA1–FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p. Nature Communications, 2017, 8, 947.	5.8	56
36	Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. Journal of Medicinal Chemistry, 2016, 59, 4697-4710.	2.9	52

#	Article	IF	CITATIONS
37	The mechanism of cell cycle regulation by v-Src. Oncogene, 2001, 20, 5941-5950.	2.6	48
38	ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells. Cell Chemical Biology, 2018, 25, 1456-1469.e6.	2.5	43
39	Next-generation phenotypic screening. Future Medicinal Chemistry, 2016, 8, 1331-1347.	1.1	39
40	Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action. Metallomics, 2018, 10, 93-107.	1.0	39
41	MISpheroID: a knowledgebase and transparency tool for minimum information in spheroid identity. Nature Methods, 2021, 18, 1294-1303.	9.0	38
42	AP-1 Differentially Expressed Proteins Krp1 and Fibronectin Cooperatively Enhance Rho-ROCK-Independent Mesenchymal Invasion by Altering the Function, Localization, and Activity of Nondifferentially Expressed Proteins. Molecular and Cellular Biology, 2006, 26, 1480-1495.	1.1	37
43	Reversal of proliferation deficits caused by chromosome 16p13.11 microduplication through targeting NFκB signaling: an integrated study of patient-derived neuronal precursor cells, cerebral organoids and in vivo brain imaging. Molecular Psychiatry, 2019, 24, 294-311.	4.1	36
44	Profiling distinct mechanisms of tumour invasion for drug discovery: imaging adhesion, signalling and matrix turnover. Clinical and Experimental Metastasis, 2009, 26, 381-397.	1.7	29
45	High-Precision Photothermal Ablation Using Biocompatible Palladium Nanoparticles and Laser Scanning Microscopy. ACS Applied Materials & Interfaces, 2018, 10, 3341-3348.	4.0	28
46	High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need. Cell Chemical Biology, 2021, 28, 338-355.	2.5	27
47	High content phenotypic screening identifies serotonin receptor modulators with selective activity upon breast cancer cell cycle and cytokine signaling pathways. Bioorganic and Medicinal Chemistry, 2020, 28, 115209.	1.4	26
48	FLIM-FRET imaging in vivo reveals 3D-environment spatially regulates RhoGTPase activity during cancer cell invasion. Small GTPases, 2011, 2, 239-244.	0.7	25
49	An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nature Communications, 2019, 10, 2901.	5.8	24
50	Quantitative phenotypic and pathway profiling guides rational drug combination strategies. Frontiers in Pharmacology, 2014, 5, 118.	1.6	22
51	N-alkynyl derivatives of 5-fluorouracil: susceptibility to palladium-mediated dealkylation and toxigenicity in cancer cell culture. Frontiers in Chemistry, 2014, 2, 56.	1.8	22
52	High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery. SLAS Discovery, 2020, 25, 770-782.	1.4	22
53	Accelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screening. Molecular and Cellular Neurosciences, 2017, 80, 198-207.	1.0	20
54	A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability. Cancer Research, 2021, 81, 5438-5450.	0.4	20

#	Article	IF	CITATIONS
55	Advancing cancer drug discovery towards more agile development of targeted combination therapies. Future Medicinal Chemistry, 2012, 4, 87-105.	1.1	19
56	Combining imaging and pathway profiling: an alternative approach to cancer drug discovery. Drug Discovery Today, 2012, 17, 203-214.	3.2	18
57	eCF309: a potent, selective and cell-permeable mTOR inhibitor. MedChemComm, 2016, 7, 471-477.	3.5	18
58	Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β. , 2021, 9, e001740.		18
59	Development of the Theta Comparative Cell Scoring Method to Quantify Diverse Phenotypic Responses Between Distinct Cell Types. Assay and Drug Development Technologies, 2016, 14, 395-406.	0.6	17
60	N-cadherin stabilises neural identity by dampening anti-neural signals. Development (Cambridge), 2019, 146, .	1.2	17
61	A computationally designed binding mode flip leads to a novel class of potent tri-vector cyclophilin inhibitors. Chemical Science, 2019, 10, 542-547.	3.7	17
62	Trichoplein binds <scp>PCM</scp> 1 and controls endothelial cell function by regulating autophagy. EMBO Reports, 2020, 21, e48192.	2.0	17
63	A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen. Molecular Cancer Therapeutics, 2020, 19, 637-649.	1.9	16
64	ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling. Oncogene, 2021, 40, 6235-6247.	2.6	16
65	Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach. Scientific Reports, 2018, 8, 5527.	1.6	15
66	Mammary Tumor Cells with High Metastatic Potential Are Hypersensitive to Macrophage-Derived HGF. Cancer Immunology Research, 2019, 7, 2052-2064.	1.6	15
67	Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. Journal of Pathology, 2013, 230, 430-440.	2.1	14
68	High-Content Analysis to Leverage a Robust Phenotypic Profiling Approach to Vascular Modulation. Journal of Biomolecular Screening, 2013, 18, 1246-1259.	2.6	13
69	Evaluation of Machine Learning Classifiers to Predict Compound Mechanism of Action When Transferred across Distinct Cell Lines. SLAS Discovery, 2019, 24, 224-233.	1.4	13
70	Global histone modification fingerprinting in human cells using epigenetic reverse phase protein array. Cell Death Discovery, 2017, 3, 16077.	2.0	12
71	Reverse Phase Protein Arrays and Drug Discovery. Methods in Molecular Biology, 2017, 1647, 153-169.	0.4	12
72	Automated <i>in vivo</i> drug screen in zebrafish identifies synapse-stabilising drugs with relevance to spinal muscular atrophy. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	12

#	Article	IF	CITATIONS
73	Chemical Interrogation of Nuclear Size Identifies Compounds with Cancer Cell Line-Specific Effects on Migration and Invasion. ACS Chemical Biology, 2022, 17, 680-700.	1.6	12
74	Reverse Phase Protein Arrays elucidate mechanisms-of-action and phenotypic response in 2D and 3D models. Drug Discovery Today: Technologies, 2017, 23, 7-16.	4.0	11
75	Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes. ACS Chemical Biology, 2022, 17, 1876-1889.	1.6	11
76	Advanced intravital subcellular imaging reveals vital threeâ€dimensional signalling events driving cancer cell behaviour and drug responses in live tissue. FEBS Journal, 2013, 280, 5177-5197.	2.2	10
77	Novel roles of PRK1 and PRK2 in cilia and cancer biology. Scientific Reports, 2020, 10, 3902.	1.6	10
78	Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma. BMC Cancer, 2020, 20, 269.	1.1	10
79	The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells. BMC Cancer, 2019, 19, 1124.	1.1	9
80	Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies. Scientific Reports, 2020, 10, 21985.	1.6	9
81	Naturally Inspired Peptide Leads: Alanine Scanning Reveals an Actinâ€Targeting Thiazole Analogue of Bisebromoamide. ChemBioChem, 2016, 17, 1621-1627.	1.3	8
82	Machine Learning Enables Live Label-Free Phenotypic Screening in Three Dimensions. Assay and Drug Development Technologies, 2018, 16, 51-63.	0.6	8
83	The retinal tyrosine kinome of diabetic Akimba mice highlights potential for specific Src family kinase inhibition in retinal vascular disease. Experimental Eye Research, 2020, 197, 108108.	1.2	8
84	Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8 ⁺ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells. Journal of Visualized Experiments, 2019, , .	0.2	7
85	Empirical drug discovery: a view from the proteome. Drug Discovery Today: Technologies, 2017, 23, 1-5.	4.0	6
86	Modelling distinct modes of tumour invasion and metastasis. Drug Discovery Today: Disease Models, 2011, 8, 103-112.	1.2	5
87	NODAL/TGFβ signalling mediates the self-sustained stemness induced by <i>PIK3CAH1047R</i> homozygosity in pluripotent stem cells. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	5
88	Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment. Molecular Oncology, 2022, 16, 1072-1090.	2.1	5
89	Assaying Calpain Activity. Methods in Molecular Biology, 2007, 370, 109-119.	0.4	4
90	Drug Screening Platforms and RPPA. Advances in Experimental Medicine and Biology, 2019, 1188, 203-226.	0.8	4

0

#	Article	IF	CITATIONS
91	High-Dimensional Profiling: The Theta Comparative Cell Scoring Method. Methods in Molecular Biology, 2018, 1787, 171-181.	0.4	3
92	Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma. ESMO Open, 2020, 5, e000707.	2.0	3
93	Application of a High-Content Screening Assay Utilizing Primary Human Lung Fibroblasts to Identify Antifibrotic Drugs for Rapid Repurposing in COVID-19 Patients. SLAS Discovery, 2021, 26, 1091-1106.	1.4	3
94	FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis. Journal of Cell Biology, 2015, 210, 2104OIA168.	2.3	1
95	A Novel High-Content Phenotypic Screen To Identify Inhibitors of Mitochondrial DNA Maintenance in Trypanosomes. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0198021.	1.4	1

96 Calpain. , 2015, , 729-732.